Read by QxMD icon Read

I-131 Therapy

Viviane B L Torres, Juliana Vassalo, Ulysses V A Silva, Pedro Caruso, André P Torelly, Eliezer Silva, José M M Teles, Marcos Knibel, Ederlon Rezende, José J S Netto, Claudio Piras, Luciano C P Azevedo, Fernando A Bozza, Nelson Spector, Jorge I F Salluh, Marcio Soares
INTRODUCTION: Cancer patients are at risk for severe complications related to the underlying malignancy or its treatment and, therefore, usually require admission to intensive care units (ICU). Here, we evaluated the clinical characteristics and outcomes in this subgroup of patients. MATERIALS AND METHODS: Secondary analysis of two prospective cohorts of cancer patients admitted to ICUs. We used multivariable logistic regression to identify variables associated with hospital mortality...
2016: PloS One
Yuan Qu, Rui Huang, Lin Li
OBJECTIVES: To compare the ablation results, therapeutic responses and adverse reactions between a low dose (1.1 GBq) or high dose (3.7 GBq) of (131)I in low-/intermediate-risk differentiated thyroid cancer (DTC) patients. The factors influencing the ablation result and therapeutic response were also analyzed. METHODS: The researchers used a random number table to randomly assign the enrolled patients to the low-dose group or high-dose group at a 1:1 ratio, and assessment of ablation result, therapeutic response, and adverse reactions evaluated 6 ± 3 months after therapy...
October 18, 2016: Annals of Nuclear Medicine
Marenza Leo, Teresa Mautone, Ilaria Ionni, Maria Antonietta Profilo, Elena Sabini, Francesca Menconi, Barbara Mazzi, Roberto Rocchi, Francesco Latrofa, Marco Nardi, Paolo Vitti, Claudio Marcocci, Michele Marinò
OBJECTIVE: Intravenous (iv) glucocorticoids (GC) (ivGC) are used for active Graves orbitopathy (GO), but factors affecting GO outcome are poorly understood. We performed a retrospective study to investigate the variables affecting GO after ivGC. METHODS: We evaluated 83 consecutive GO patients treated with ivGC but not orbital radiotherapy (ORT) and re-examined them after a median of 47 months. The endpoints were the relationships between GO outcome or additional treatments with age, sex, smoking habits, thyroid volume, thyroid treatment, time since thyroid treatment, antithyroid-stimulating hormone receptor antibodies (TRAb), GO duration, GO features, and follow-up time...
October 2016: Endocrine Practice
Raja N Mahesh, Pranay R Korpole, Ganesh Shetty, Handrashekar U Kudru, Shivashankara K Nagiri
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
Frederik A Verburg, Markus Luster, Luca Giovanella
No abstract text is available yet for this article.
October 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Na Liu, Zhaowei Meng, Qiang Jia, Jian Tan, Guizhi Zhang, Wei Zheng, Renfei Wang, Xue Li, Tianpeng Hu, Arun Upadhyaya, Pingping Zhou, Sen Wang
(131)I treatment is an important management method for patients with differentiated thyroid cancer (DTC). Unsuccessful (131)I ablation drastically affects the prognosis of the patients. This study aimed to analyze potential predictive factors influencing the achievement of a disease-free status following the first (131)I therapy. This retrospective review included 315 DTC patients, and multiple factors were analyzed. Tumor size, pathological tumor stage, lymph node (LN) metastasis, distant metastasis, American Thyroid Association recommended risks, pre-ablation thyroglobulin (Tg), and thyroid stimulating hormone (TSH) displayed significant differences between unsuccessful and successful group...
October 10, 2016: Scientific Reports
Valentina Zilioli, Alessia Peli, Maria Beatrice Panarotto, Giancarlo Magri, Ahmed Alkraisheh, Christiane Wiefels, Carlo Rodella, Raffaele Giubbini
The purpose of this prospective study was to determine the incremental diagnostic value of single photon emission computed tomography/computed tomography with iodine-131 over planar whole body scan in the staging of patients with differentiated thyroid carcinoma. A total of 365 patients (270 female, 95 male) with differentiated thyroid carcinoma were treated with radioiodine therapy for thyroid remnant ablation with radical intent after thyroidectomy between January 2013 and November 2014. In addition to planar whole body scan, single photon emission computed tomography/computed tomography of neck and chest were performed...
September 29, 2016: Endocrine
Ali Afshar-Oromieh, John W Babich, Clemens Kratochwil, Frederik L Giesel, Michael Eisenhut, Klaus Kopka, Uwe Haberkorn
The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors (123)I-MIP-1972 and (123)I-MIP-1095. A clinical breakthrough followed in 2011 with (68)Ga-PSMA-11 for PET imaging and (131)I-MIP-1095 for endoradiotherapy of metastatic prostate cancer...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
L Y Li, H L Yi
Thyroid carcinoma is one of the most common cancer in the head and neck and its incidence shows an increasing tendency. Due to the special anatomical location of thyroid carcinoma, patients will have a bad prognosis outcome when cancer invades larynx and trachea. Surgical treatment is still a preferred therapy for thyroid carcinoma with laryngotracheal invasion, because it has the advantages such as high survival rate, low recurrence rate, relieving of airway obstruction, improving of postoperative quality of life...
September 7, 2016: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
Megan Fracol, Jashodeep Datta, Lea Lowenfeld, Shuwen Xu, Paul J Zhang, Carla S Fisher, Brian J Czerniecki
BACKGROUND: We previously demonstrated a progressive loss of the anti-human epidermal growth factor receptor 2 (HER2) CD4+ T-helper type 1 (Th1) response during HER2(pos) breast tumorigenesis. This loss is associated with residual disease following neoadjuvant therapy and increased risk of recurrence. In this study, we assessed the fate of anti-HER3 Th1 immunity during breast tumorigenesis. METHODS: Peripheral blood from 131 subjects, including healthy donors (HDs), patients with benign breast disease (BD), ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC), was collected...
September 23, 2016: Annals of Surgical Oncology
Mehran Pashnehsaz, Abbas Takavar, Sina Izadyar, Seyed Salman Zakariaee, Mahmoud Mahmoudi, Reza Paydar, Parham Geramifar
Iodine-131 (I-131) therapy is one of the conventional approaches in the treatment of patients with differentiated thyroid carcinoma (DTC). The radioiodine agents also accumulate in the other organs that cause pain and damage to the patients. Radioiodine therapy is associated with various gastrointestinal (GI) toxicities. In this study, GI side effects of the radioiodine therapy were investigated. GI toxicities of the radioiodine therapy were studied in 137 patients with histologically proven DTC in Jun-Nov 2014...
September 2016: World Journal of Nuclear Medicine
Mei Lin, Junxing Huang, Xingmao Jiang, Jia Zhang, Hong Yu, Jun Ye, Dongsheng Zhang
Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed. AntiAFPMcAb (Monoclonal antibody AFP) is exploited for targeting. The plasmids pHRE-Egr1-HSV-TK are achieved by incorporation of pEgr1-HSV-TK and pHRE-Egr1-EGFP. Restriction enzyme digestion and PCR confirm the recombinant plasmids pHRE-Egr1-HSV-TK are successfully constructed...
2016: Scientific Reports
Niccolo Passoni, Bishoy Gayed, Payal Kapur, Arthur I Sagalowsky, Shahrokh F Shariat, Yair Lotan
PURPOSE: To assess if a panel of cell-cycle markers could improve the discrimination of European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) models in predicting recurrence and progression of high-grade non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Between January 2007 and January 2012, every patient with high-grade NMIBC treated with transurethral resection of bladder underwent immunohistochemical staining for 5 biomarkers (p21, p27, p53, KI-67, and cyclin E1)...
September 13, 2016: Urologic Oncology
Tetsuhide Ito, Lingaku Lee, Robert T Jensen
INTRODUCTION: Neuroendocrine tumors(NETs), once thought rare, are increasing in frequency in most countries and receiving increasing-attention. NETs present two-treatment problems. A proportion is aggressive and a proportion has a functional, hormone-excess-state(F-NET) each of which, must be treated. Recently, there have been many advances, well-covered in reviews/consensus papers on imaging-NETs; new, novel anti-tumor treatments and understanding their pathogenesis. However, little attention has been paid to advances in the treatment of the hormone-excess-state...
September 16, 2016: Expert Opinion on Pharmacotherapy
Li-Hua Zhang, Jing-Yan Li, Qi Tian, Shuang Liu, Hong Zhang, Sheng Liu, Jiu-Gen Liang, Xian-Ping Lu, Ning-Yi Jiang
The aims of the present study were to analyze the outcomes of pregnancy, after (131)I treatment, in patients of reproductive age with Graves' hyperthyroidism and to investigate the effects, if any, of the (131)I treatment on the mothers and newborns. From 2009 to 2014, 257 pregnant female patients with Graves' hyperthyroidism in the outpatients at the Department of Nuclear Medicine and 166 healthy pregnant women from the Department of Obstetrics at Sun Yat-Sen Memorial Hospital were included in our study. They were divided into a (131)I therapy group (n = 130) and an anti-thyroid drug (ATD) group (n = 127) according to their therapy before conception...
September 12, 2016: Journal of Radiation Research
W Xia, D Li, G Wang, J Ni, J Zhuang, M Ha, J Wang, Y Ye
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Currently, the clinical strategies available for the treatment of HCC remain insufficient for the poor prognosis. Sodium/iodide symporter (NIS)-based radioiodine therapy is proposed as a promising therapeutic strategy for the treatment of HCC. However, it is difficult for HCC cells to trap iodine for the lower expression of NIS. Small activating RNA (saRNA) is a newly identified small double-stranded RNA (dsRNA) that can induce endogenous gene expression by targeting promoter sequences...
September 9, 2016: Cancer Gene Therapy
O Zengin, M E Onder, A Kalem, M Bilici, I H Türkbeyler, Z A Ozturk, B Kisacik, A M Onat
BACKGROUND: Rheumatoid arthritis (RA) is the most common chronic inflammatory disorder and is associated with progressive destruction of synovial joints and physical disability. Therapies with known benefits include disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, as well as more recent biologic agents, such as tumor necrosis factor inhibitors (anti-TNF therapy). METHOD: This was a retrospective study, which included 205 RA and 112 early RA (ERA) patients from the Rheumatology Clinic at Gaziantep University School of Medicine Research Center as well as 104 healthy controls...
September 7, 2016: Zeitschrift Für Rheumatologie
Christian Keller, Jochen Müller-Ehmsen
The HOPE-3-Trial investigated the effect of primary prevention on cardio- and neurovascular events in patients without known atherosclerotic disease, but with intermediate risk. In a factorial design Rosuvastatin 10 mg, Candesartan 16 mg/HCT 12.5 mg or both were compared with placebo. Rosuvastatin effectively lowered LDL-cholesterol and the rate of cardio- and neurovascular complications with a NNT of approximately 500/year without detectable effect on mortalitiy. Candesartan 16 mg/HCT 12.5 mg did not influence any endpoint, however, the predefined subgroup of patients with hypertension level I had a benefit...
September 2016: Deutsche Medizinische Wochenschrift
Mustafa Top, Ozge Er, Gulsah Congur, Arzum Erdem, Fatma Yurt Lambrecht
Topoisomerase I inhibitor topotecan (TPT) is the only single-agent therapy certified for the remedy of repetitive small cell lung cancer (SCLC). In this study, TPT was labeled with (131)I via iodogen method and its quality control was determined using thin layer radiochromatography and paper electrophoresis methods. Intracellular uptake study was carried out with human lung adenocarcinoma cell line (A-549) and human lung fibroblast cell line (WI-38). The interaction of (131)I-TPT with healthy DNA and cancer DNA was also investigated using single-use sensor technology combined with electrochemical impedance spectroscopy (EIS)...
November 1, 2016: Talanta
Dong-Yeop Shin, Byung Hyun Byun, Kyeong Min Kim, Joo Hyun Kang, Ilhan Lim, Byung Il Kim, Seung-Sook Lee, Chang Woon Choi, Hye Jin Kang, Sang Moo Lim
PURPOSE: The aim of this study was to assess the clinical activity and toxicity of (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma (DLBCL) who were treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone). METHODS: Patients who had been diagnosed with advanced stage (Ann Arbor III or IV) or bulky stage II DLBCL and achieved complete or partial response after six to eight cycles of R-CHOP were enrolled...
October 2016: Cancer Chemotherapy and Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"